Indaptus Therapeutics is trading at $1.29 (-10.42%) as the stock faces a second day of sharp selling driven by post-rally profit-taking following a steep multi-day rebound.
- No fresh company-specific catalysts have been identified, suggesting the move is a technical correction after the recent price surge.
- Broader sector weakness is adding pressure, with the XBI biotechnology ETF falling 3.15% during the session.
- The stock remains vulnerable to extended short-term selling due to high volatility and significant price swings over the past week.